立体定向体部放疗(SBRT)治疗乳腺癌医学上无法手术的肺和肝寡转移的前瞻性非随机2期研究最终结果
这项前瞻性非随机2期试验(NCT02581670)于2015至2021年入组64例乳腺癌肺和/或肝寡转移患者共90个病灶,接受SBRT,主要终点为局部控制(LC)和治疗相关毒性。1年LC为94.9%,中位总生存期(OS)为16.5个月,1、2、3年OS分别为87.5%、60.9%、51.9%。作者认为SBRT是安全有效的选择,局部控制率很高,可能需要优化患者选择以改善生存结局并减少远处进展。
要点
- 前瞻性非随机2期试验纳入64例乳腺癌肺/肝寡转移患者,共90个病灶接受SBRT。
- 1年局部控制率为94.9%,中位局部控制未达到。
- 中位OS为16.5个月,1、2、3年OS分别为87.5%、60.9%、51.9%。
核心结论
- 作者认为SBRT是乳腺癌寡转移患者安全且有效的选择,局部控制率很高。
- 作者认为可能需要优化患者选择以改善生存结局并降低远处进展率。
研究设计与样本
- 这是一项前瞻性非随机2期试验(NCT02581670),入组时间为2015年至2021年。
- 纳入标准包括年龄>18岁、ECOG 0-2、乳腺癌诊断、最多4个肺/肝病灶(最大直径<5 cm)、转移灶局限于肺和肝或肺外/肝外病灶对全身治疗稳定或缓解。
- 主要终点为局部控制(LC)和治疗相关毒性,次要终点包括总生存期(OS)、无远处转移生存期(DMFS)、至下次全身治疗时间(TTNS)、多进展无进展生存期(PPFS)。
- 研究纳入64例患者,共90个病灶接受SBRT。
主要发现
- 1年和2年局部控制率分别为94.9%和91%,3年局部控制率为91%,中位局部控制未达到。
- 中位OS为16.5个月,1、2、3年OS分别为87.5%、60.9%、51.9%。
- 中位DMFS为8.3个月,1、2、3年DMFS分别为38.1%、20.6%、16%。
- 单因素分析显示,SBRT的局部缓解与更好的OS、DMFS和STFS有统计学关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To report mature results for local control and survival in oligometastatic (OM) breast cancer patients treated with stereotactic body radiotherapy (SBRT) on lung and/or liver lesions in a phase II trial. METHODS: This is a prospective non-randomized phase II trial (NCT02581670) which enrolled patients from 2015 to 2021. Eligibility criteria included: age > 18 years, ECOG 0-2, diagnosis of breast cancer, maximum of 4 lung/liver lesions (with a maximum diameter < 5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy. The primary end-points were local control (LC) and treatment-related toxicities. The secondary end-points included overall survival (OS), distant metastasis-free survival (DMFS), time to next systemic therapy (TTNS), poly-progression free survival (PPFS). RESULTS: The study included 64 patients with a total of 90 lesions treated with SBRT. LC at 1 and 2 years was 94.9 %, 91 % at 3 years. Median local control was not reached. Median OS was 16.5 months, OS at 1, 2 and 3 years was 87.5 %, 60.9 % and 51.9 %, respectively. Median DMFS was 8.3 months, DMFS at 1, 2 and 3 years was 38.1 %, 20.6 % and 16 % respectively. At univariate analysis, local response to SBRT was found to be statistically linked with better OS, DMFS and STFS. CONCLUSION: SBRT is a safe and valid option in oligometastatic breast cancer patients, with very high rates of local control. An optimal selection of patients is likely needed to improve survival outcomes and reduce the rate of distant progression.
引用
- Franceschini D, Franzese C, Comito T, et al. Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer. Radiother Oncol. 2024. PMID: 38522597. doi:10.1016/j.radonc.2024.110240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。